 |
|
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome
Does Early Withdrawal of Causative Drugs Decrease the Risk of Death?
Ignacio Garcia-Doval, MD;
Laurence LeCleach, MD;
Hélène Bocquet, MD;
Xose-Luis Otero, PhD;
Jean-Claude Roujeau, MD
Arch Dermatol. 2000;136:323-327.
Background Withdrawal of the drug(s) that cause severe cutaneous adverse reactions is usually recommended without proof that it alters the course of those reactions.
Objective To determine whether the timing of causative drug withdrawal is related to the prognosis of patients with toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS).
Design A 10-year observational study (January 1, 1987, through October 30, 1997) of patients admitted to a dermatological intensive care unit, using binary logistic regression analysis.
Setting A single referral unit in a university hospital.
Patients Consecutive sample of 203 patients with TEN or SJS. Exclusion criteria included causative drug undetermined, lack of information on disease evolution, the date of causative drug(s) withdrawal, or the date when the first definite sign of TEN or SJS appeared.
Main Outcome Measure Death before hospital discharge.
Results One hundred thirteen patients were included; 74 had TEN and 39 had SJS; 20 died. The drug causing TEN or SJS was withdrawn early in 64 patients and late (after the first definite sign of TEN or SJS) in 49 patients. After adjustment for confounding variables (age, maximum extent of detachment, admission year, human immunodeficiency virus status), our model showed that the earlier the causative drug was withdrawn, the better the prognosis (odds ratio, 0.69 for each day; 95% confidence interval, 0.53-0.89). Patients exposed to causative drugs with long half-lives had an increased risk of dying (odds ratio, 4.9; 95% confidence interval, 1.3-18.9). The variables did not interact.
Conclusions Prompt withdrawal of drug(s) that are suspected to cause SJS or TEN may decrease mortality. Prompt withdrawal of causative drugs should be a priority when blisters or erosions appear in the course of a drug eruption.
From the Department of Dermatology, Hospital Provincial de Pontevedra, Pontevedra, Spain (Dr Garcia-Doval); the Department of Dermatology, Hôpital Henri Mondor, Université Paris XII, Créteil, France (Drs LeCleach, Bocquet, and Roujeau); and the Biostatistics Unit, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain (Dr Otero).
RELATED ARTICLES
Improving the Outcome of Patients With Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome
Robert S. Stern
Arch Dermatol. 2000;136(3):410-411.
EXTRACT
| FULL TEXT
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2000;136(3):438-439.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Management of toxic epidermal necrolysis and related syndromes
Mukasa and Craven
Postgrad. Med. J. 2008;84:60-65.
ABSTRACT
| FULL TEXT
Cutaneous Reactions to Drugs in Children
Segal et al.
Pediatrics 2007;120:e1082-e1096.
ABSTRACT
| FULL TEXT
Use of Intravenous Immunoglobulin in Children With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Seven Cases and Review of the Literature
Metry et al.
Pediatrics 2003;112:1430-1436.
ABSTRACT
| FULL TEXT
Reducing Medication Errors and Increasing Patient Safety: Case Studies in Clinical Pharmacology
Benjamin
J Clin Pharmacol 2003;43:768-783.
ABSTRACT
| FULL TEXT
Recurrent Erythema Multiforme/Stevens-Johnson Syndrome: Response to Mycophenolate Mofetil
Davis et al.
Arch Dermatol 2002;138:1547-1550.
FULL TEXT
Amifostine-induced Toxic Epidermal Necrolysis during Radiotherapy: a Case Report
Demiral et al.
Jpn J Clin Oncol 2002;32:477-479.
ABSTRACT
| FULL TEXT
Discontinuing Drugs Can Save Patients with TEN and SJS
Journal Watch Dermatology 2000;2000:1-1.
FULL TEXT
Improving the Outcome of Patients With Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome
Stern
Arch Dermatol 2000;136:410-411.
FULL TEXT
|
